Medication info
Trantaduo Tablet 2.5/500 mg

Trantaduo Tablet 2.5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Unimed Pharmaceutical Co., Ltd.
Appearance
Light yellow, convex, oval-shaped film-coated tablets
Packaging
30 tablets/box [(6 tablets/PTP x 5 units)]
Approval status
Active

MFDS item code 202400702 · Approved 2024.03.29 · Insurance code 649508470

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, the initial dose of this medicine is 2.5/500 mg twice daily, 1 tablet per dose; the dose may be increased to 2.5/1000 mg twice daily, 1 tablet per dose. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s existing metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 3. Precautions for administration to the following patients in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Do not administer to the following patients in Precautions for Use).

Ingredients

Manufacturer
Unimed Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar in patients with type 2 diabetes taking both linagliptin and metformin. It supports effective blood sugar management when combined with dietary and exercise therapy. Therefore, this medication is suitable for patients with type 2 diabetes who require blood sugar control.

How to take

Adult dose

The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, the initial dose of this medicine is 2.5/500 mg twice daily, 1 tablet per dose; the dose may be increased to 2.5/1000 mg twice daily, 1 tablet per dose. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s existing metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 3. Precautions for administration to the following patients in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Do not administer to the following patients in Precautions for Use).

Precautions

This medication is primarily used to control blood sugar, as it contains two active ingredients that work together to lower blood sugar levels. This medication can cause a rare but serious side effect called lactic acidosis, so it should not be administered to patients with impaired kidney function or liver dysfunction. Moreover, patients with certain types of diabetes, severe heart disease, acute infections, dehydration, or acute myocardial infarction may be at risk if using this medication. It is not recommended for use in pregnant or breastfeeding women, and consultation with a physician is essential before administration. This medication can cause hypoglycemia, so careful monitoring of blood sugar changes is necessary, especially when used with other hypoglycemic agents or insulin. Elderly patients with impaired kidney function or those taking medications that may affect kidney function should undergo regular kidney function tests. During the course of taking this medication, rare side effects such as acute pancreatitis or blistering dermatitis may occur, so if persistent abdominal pain or skin abnormalities are observed, the physician should be informed immediately. Additionally, this medication may lead to vitamin B12 deficiency, so if used long-term, blood tests to check vitamin B12 levels are necessary. This medication can interact with other drugs, so it is crucial to inform the doctor or pharmacist of any current medications. Patients should avoid excessive alcohol consumption while taking this medication and may need to stop taking it for a certain period prior to surgeries or radiological examinations. Safety in children and adolescents has not been established, so it is not recommended for children under 10 years old. This medication should be stored in a tightly closed container, away from moisture and out of reach of children, and transferring the medication to other containers should be avoided. In case of an overdose, immediate medical attention should be sought, especially if symptoms of lactic acidosis occur.

Side effects

  • lactic acidosis
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 84 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficient vitamin B12
  • oral ulcers
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hypertension
  • itching
  • insomnia
  • depression
  • anxiety
  • benign prostatic hyperplasia
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • confusion
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air and moisture. The storage temperature should be maintained between 1°C and 30°C. This helps maintain the effectiveness and safety of the medication over time.

Appearance and packaging

Appearance

Light yellow, convex, oval-shaped film-coated tablets

Package unit

30 tablets/box [(6 tablets/PTP x 5 units)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.